Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial-Reference-Cited by-同舟云学术

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial

Published:2014-04-11 Issue:9 Volume:53 Page:1654-1663
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Bao C.,Huang F.,Khan M. A.,Fei K.,Wu Z.,Han C.,Hsia E. C.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/53/9/1654/5298677/keu132.pdf

Reference24 articles.

1. Emerging drugs for axial spondyloarthritis including ankylosing spondylitis

2. Rheumatic Diseases in China

4. Update on the Management of Spondyloarthritis in Asian Countries

5. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A department of veterans affairs cooperative study

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations;Expert Opinion on Biological Therapy;2024-08-02

2. The Use of TNF-α Inhibitors in Active Ankylosing Spondylitis Treatment;Cureus;2024-06-01

3. Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies;Rheumatology and Therapy;2024-03-15

4. Dynamics of T-cell receptor repertoire in patients with ankylosing spondylitis after biologic therapy;International Immunopharmacology;2024-01

5. The incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: a systematic review and network meta‐analysis;Arthritis & Rheumatology;2023-12-20